Search

Displaying results 2671 - 2680 of 8412 in total
  1. Drug

    Benznidazole

    go.drugbank.com/drugs/DB11989
    ApprovedInvestigational

    Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  2. Drug

    Almitrine

    go.drugbank.com/drugs/DB01430
    Approved

    Almitrine is a respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies.

    Synonyms: 2,4-Bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine
  3. Drug

    Pomaglumetad methionil

    go.drugbank.com/drugs/DB05096
    Investigational

    LY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. … Further studies are planned or are ongoing to learn more about the safety and effectiveness, including determining an optimal therapeutic dose for LY2140023.

  4. Drug

    Ocaperidone

    go.drugbank.com/drugs/DB06229
    Experimental

  5. Drug

    Fedratinib

    go.drugbank.com/drugs/DB12500
    ApprovedInvestigational

    [A183176,L8090] It is an anilinopyrimidine derivative.[A183188] Fedratinib was granted FDA approval on August 16, 2019.[L8090]

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  6. Drug

    Tegaserod

    go.drugbank.com/drugs/DB01079
    ApprovedWithdrawn

    Novartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C). It was, however, voluntarily withdrawn from widespread use in the ...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  7. Drug

    Desipramine

    go.drugbank.com/drugs/DB01151
    Approved

    The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. … They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  8. Drug

    Ouabain

    go.drugbank.com/drugs/DB01092
    Approved

    It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-exchanging ATPase.

  9. Drug

    SX-682

    go.drugbank.com/drugs/DB19210
    Investigational

    clinical trial NCT04574583 (Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With Bintrafusp Alfa (M7824 or Tgf-beta "Trap"/pd-l1

  10. Drug

    Cevimeline

    go.drugbank.com/drugs/DB00185
    Approved

    Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates